Myriad Genetics, Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products. The company offers molecular diagnostic products comprising BRACAnalysis for assessing a woman's risk for breast and ovarian cancer; COLARIS for determining a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP for assessing a person's risk of developing colon cancer; MELARIS for determining a person's risk of developing melanoma; and THERAGUIDE 5-FU for assessing a patient's risk of developing 5-FU toxicity. It markets these products through its own sales force in the United States and through marketing collaborations in selected foreign countries. The company's developing therapeutic products include Flurizan, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Azixa, a Phase II clinical trial product for solid primary and metastatic brain tumors; MPC-2130, which is in Phase I clinical trial for the treatment of hematologic cancer; MPC-0920, a Phase I clinical trial product for thrombosis; and Vivecon, which is in late-stage preclinical development for the treatment of AIDS. Myriad Genetics was founded in 1991 and is headquartered in Salt Lake City, Utah.